FATE - Fate Therapeutics Inc Company Long-Term Liabilities

Public company logo of Fate Therapeutics Inc (FATE)

Fate Therapeutics, Inc. (FATE) is a leader in developing iPSC-based anti-tumor agents while engaging in intense patent battles with biopharma behemoths. This price chart serves as an indicator of market expectations, with long-term debt standing at 0.07. The business relies on the serial production of immunotherapeutic agents, aiming to transform high-tech cancer treatment into a mass-market, affordable product.

fatetherapeutics.com (FATE) Company Long-Term Debt: for the period 07/04/2022 - 10/30/2026

Fate Therapeutics Corp (FATE) - metric breakdowns and financial figures

- share price and expert price forecast:
Share Price fatetherapeutics.com|FATE - Analyst Consensus Forecast
- market capitalization statistics:
Market Valuation Fate Therapeutics|FATE - Enterprise Value
- shareholders' equity book value data:
Net Asset Value per Share Fate Therapeutics|FATE - Company Book Value|Market Value to Book Value fatetherapeutics.com|FATE - Cumulative Company Assets
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Fate Therapeutics, Inc.|FATE - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Fate Pharma|FATE - Company Total Debt|Debts to Book Capitalization Fate Therapeutics|FATE - Company Long-Term Debt|Company Short-Term Loans and Borrowings Fate Therapeutics|Immediate Liquidity fatetherapeutics.com
- earnings and market multiples details:
FATE - Net Profit
Fundamental company valuation:FATE (fatetherapeutics.com)
Brand item of Fate Therapeutics, Inc.

Fate Therapeutics, Inc. (FATE) is scaling its cell therapy development through strategic partnerships with global pharmaceutical behemoths. An analysis of the business's long-term debt volume allows for an assessment of the funding stability for these high-tech research initiatives. This metric aggregates obligations with maturities exceeding one year, reflecting the company's debt management strategy. The stability of this metric confirms the issuer's solvency, while sharp deviations signal structural changes in capital.

Competitors of Fate Therapeutics, Inc. (FATE)

ONC: Company Long-Term Indebtedness|Halozyme - Company Long-Term Debts|Revolution Medicines Inc (RVMD) - Company Long-Term Liabilities|AAPG: Company Long-Term Debts|Long-Term Debt CG Oncology Therapeutics (CGON)|Company Long-Term Debt UroGen Pharma Ltd.|BCAX: Company Long-Term Loans and Borrowings|Company Long-Term Liabilities PSNL (Personalis)|ERAS (Erasca Inc) - Company Long-Term Loans and Borrowings|Company Long-Term Debts DCTH (Delcath)|YMAB - Company Long-Term Liabilities|AURA: Company Long-Term Liabilities|CADL - Company Long-Term Debts|Accuray (ARAY) - Company Long-Term Debt|SELLAS Life Sciences Group - Company Long-Term Loans and Borrowings|ACTU (Actuate Therapeutics, Inc) - Company Long-Term Debts|Long-Term Debt Citius Oncology Inc CTOR|Company Long-Term Debts HURA|TARA: Long-Term Liabilities|Company Long-Term Debts WHWK (Aadi Bioscience)|Company Long-Term Debts TScan Therapeutics Inc TCRX|CSBR: Company Long-Term Liabilities|XBiotech Inc. - Amount of Long-Term Liabilities|CVM: Company Long-Term Debts|Long-Term Debt ostherapies.com (OSTX)|Company Long-Term Liabilities RADX|ARTV: Company Long-Term Loans and Borrowings|Company Long-Term Liabilities ANL (Adlai Nortye Ltd.)|Amount of Long-Term Liabilities VERU|Company Long-Term Debts TPST (Tempest Therapeutics)|Company Long-Term Loans and Borrowings XLO|Enochian BioSciences - Company Long-Term Debts|Long-Term Debt Mural Oncology plc|kairospharma.com (KAPA) - Company Long-Term Debt|OnKure Therapeutics - Company Long-Term Loans and Borrowings|GDTC (CytoMed Therapeutics Ltd) - Company Long-Term Debts|Company Long-Term Debts Curis Corp|Company Long-Term Debt Apollomics, Inc. (APLM)|THAR: Long-Term Liabilities|Company Long-Term Debts ADVB (Advanced Biomed)|Genprex Inc (GNPX) - Long-Term Debt|CLDI: Company Long-Term Liabilities|SBFM - Company Long-Term Debts|XBIO (xeneticbio.com) - Company Long-Term Liabilities|SLRX: Amount of Long-Term Liabilities|PPBT (Purple Biotech Corp) - Company Long-Term Debts|AON (AONC) - Long-Term Debt Volume|Company Long-Term Debts BGNE|Company Long-Term Liabilities checkpointtx.com CKPT|Company Long-Term Debt Elevation Oncology, Inc. ELEV|Long-Term Debt Volume iCAD Inc. (ICAD)|IKNA: Company Long-Term Liabilities|Company Long-Term Loans and Borrowings NTBL (Notable Labs Corp)|VIRX: Company Long-Term Debts|MOR - Long-Term Debt Volume|Company Long-Term Debt NAYA Biosciences Inc.|Company Long-Term Indebtedness AAPGV (Ascentage Pharma Group International)